[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"photobiomodulation-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:photobiomodulation-therapy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100627845","blue-light-for-donor-site-healing-in-burn-patients-100627845",false,"NCT07453927","Blue Light for Donor Site Healing in Burn Patients","Blue Light in the Treatment of Donor Site in Burn Patient: a Controlled Clinical Trial","CGU01_BL","Inclusion Criteria:\n\n* Patients with intermediate-deep burns with Total Body Surface Area (TBSA) \\> 10% requiring surgical treatment with escharectomy, presenting at least two Donor Site.\n* Patients over 18 years of age;\n* Patients who have signed the informed Consent Form (ICF) and understood the purpose of the study, or, if unable to give consent personally due to their condition, their legal guardian.\n\nExclusion Criteria:\n\n* Intermediate-deep burns TBSA \\\u003C 10% or superficial burns;\n* Patients under the age of 18;\n* Patients who are participating in other clinical trials with drugs or medical devices;\n* Patients with neoplasms or other conditions requiring the use of cytostatic or immunosuppressive drugs;\n* Patients with conditions that induce skin photosensitivity;\n* Pregnant or breastfeeding women;\n* Patients or relatives who are unable to understand the purposes of the trial;","ALL","18 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether blue light (BL) photobiomodulation can improve the healing of donor site (DS) wounds in patients with burn injuries who are treated surgically. This study will investigate whether adding BL therapy to the usual treatment can improve healing and patient outcomes in adult patients with intermediate and deep burns.\n\nThe main questions it aims to answer are:\n\n* Does the use of BL therapy combined with standard treatment reduce the healing time of DS compared with standard treatment alone?\n* Does BL therapy improve wound conditions, reduce pain, and decrease signs of infection during the healing process?\n* Is BL therapy safe and well tolerated when applied to DS?\n* Does the treatment improve the long-term quality of the scar after healing?\n\nResearchers will compare DS areas treated with standard care alone to DS areas treated with standard care plus BL therapy to see whether BL improves healing outcomes. Each participant will serve as their own comparison: two different DS areas on the same patient will receive the two different treatments.\n\nParticipants will:\n\n* Receive the standard treatment for DS, which includes routine wound care and dressing\n* Receive BL therapy on one DS area in addition to the standard treatment, while another DS area will receive standard treatment alone\n* Attend regular clinical evaluations where clinicians will assess wound healing and the condition of the wound bed\n* Report their pain levels using a simple numeric scale during the healing period\n* Undergo skin swabs to detect possible signs of infection\n* Be monitored for any local side effects, such as redness, burning sensation, warmth, itching, or skin irritation related to the light treatment\n\nAfter the DS have completely healed, participants will return for follow-up visits at 1 month and 3 months. During these visits, researchers will evaluate the quality of the scars and monitor for any late side effects.",[27,28,29,30],"Donor Site Complication","Burn","Photobiomodulation Therapy","Blue Light",[32,33,34,35,36],"donor site","burns","photobiomodulation","blue light","healing","RECRUITING","2026-03-31",{"date":40,"type":41},"2026-04-06","ACTUAL",{"date":43,"type":41},"2025-09-29",{"date":45,"type":21},"2026-09-28",{"name":47,"class":48},"AUSL Romagna Rimini","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":49},"100582685","light-reflection-on-human-skin-in-whole-body-photobiomodulation-therapy-100582685","NCT06866522","Light Reflection on Human Skin in Whole-Body Photobiomodulation Therapy","Light Reflection on Human Skin in Whole-Body Photobiomodulation Therapy: Clinical Trial","Inclusion Criteria:\n\n* male and female\n* age between 18 and 30 years\n* body mass index (BMI) between 18.5 and 29.9 kg\u002Fm2.\n\nExclusion Criteria:\n\n* tattoo in the light reflection assessment areas\n* history of skin cancer\n* skin lesions such as open wounds in the mid-thigh, abdomen, biceps brachii, back and calf\n* patients with cognitive difficulty reporting thermal sensation",true,"30 Years",{"count":60,"type":21},72,[24],"Photobiomodulation therapy (PBMT) is based on exposing biological tissues to low-intensity light, with effects depending on the light-tissue interaction. When irradiated without skin contact, part of the incident light is reflected and lost. In this context, the amount of reflected light in PBMT applied without skin contact, as well as the influence of skin phototype, has not yet been established. Objective: To quantify the reflection of light from PBMT on the skin of men and women aged 18 to 30 years, considering skin phototypes. Methodology: Participants will be divided into three groups based on skin phototype (Group 1: phototypes I and II; Group 2: phototypes III and IV; Group 3: phototypes V and VI) and sex. They will be subjected to whole-body PBMT with red light (660 nm; 31.85±3.85 mW; 45.50±5.07 mW\u002Fcm²) and infrared light (850 nm; 25.29±2.99 mW; 36.13±4.27 mW\u002Fcm²) at 20 cm from the light-emitting source, with measurement of light reflection in the regions of the brachial biceps, abdomen, lumbar, anterior and posterior thigh, and calf using a power and energy analyzer (powermeter PM100D and sensor S130C, 0.7 cm²). Data will be analyzed for normality and groups were compared with a significance level of 5%",[29,64],"Phototype",[34,66,67,68,69],"low-level laser therapy","skin optics","melanin","light reflection","2025-03-07",{"date":72,"type":41},"2025-03-12",{"date":74,"type":41},"2023-11-27",{"date":76,"type":21},"2025-07-20",{"name":78,"class":48},"Universidade Federal de Sao Carlos",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":49},"100565304","early-phase-1-led-therapy-for-third-molar-surgery-100565304","NCT06640439","LED Therapy for Third Molar Surgery","LED Therapy Using 830 Nm in the Mandibular Third Molar Surgery: Double-blind Randomized Clinical Trial.","LTTMS","Inclusion Criteria:\n\n1. Healthy Asians;\n2. 20-55 years old;\n3. Having mandibular third molars that are inappropriately erupted and need to be extracted due to caries, orthodontic reasons and\u002For periodontal disease;\n\nExclusion Criteria:\n\n1. Underlying diseases: diabetes, cardiovascular disease, coagulation disorder, osteoporosis, hypertension, neurological disease, psychological disorder, tumor, systemic infection or cyst at the extraction site;\n2. Women who are preparing for pregnancy, pregnant or breastfeeding;\n3. Medication history: use of analgesics, anti-inflammatory drugs and\u002For antibacterial drugs 2 weeks before tooth extraction, need for systemic medication other than acetaminophen after surgery, allergy to acetaminophen, use of anticoagulants, bisphosphonates;\n4. Bad habits, such as addicted to smoking, drinking, etc.;\n5. Volunteers who have recently participated in other clinical trials;","20 Years","55 Years",{"count":90,"type":21},50,[92],"EARLY_PHASE1","LED Therapy for third molar surgery",[95,96,29,97],"Molar, Third","Photobiomodulation","Third Molar Surgery",[34,99,100,101],"LED","830 nm","third molar surgery","NOT_YET_RECRUITING","2024-10-10",{"date":105,"type":41},"2024-10-15",{"date":107,"type":21},"2024-10-14",{"date":109,"type":21},"2025-04-14",{"name":111,"class":48},"Huashan Hospital"]